BLS — BLS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$255.28m
- AU$250.42m
- AU$74.23m
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN
Australia's BLS Pharmaceutical soars on strong full-year results
Brief: BLS Pharmaceuticals Posts FY26 Adjusted EBITDA Of A$19 MLN
Australia's BLS Pharmaceuticals gains on agreement to commercialise Trexapharm
Brief: BLS Pharmaceuticals Says Agreement With Trexapharm For Commercialisation Of Trexavive
Brief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal
Brief: Bioxyne Signs Manufacturing Agreement With Global Cannabis Leader, Aurora Cannabis
Australia's Bioxyne hits five-month high on commercialising psilocybin capsules
Brief: Bioxyne Commercialises GMP-Manufactured Psilocybin Capsules
Brief: Bioxyne Reports Qtrly Revenue A$17.2 Mln
Brief: Bioxyne's Unit Enters Manufacturing Agreement With Remidose Latam Srl
Brief: Bioxyne Executed Exclusive Import, Manufacture And Supply Agreement With Curaleaf International For Australia